OptiKira LLC, a Cleveland biotechnology company that is developing treatments for blindness and other diseases caused by progressive cell death, has received a $1.6 million Phase II Small Business Innovation Research grant from the federal government to support what it called “continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa.”
The grant money will be used “to advance one or more of OptiKira’s most promising compounds into investigational new drug-enabling studies,” the company said in a news release issued on Thursday, May 30.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published May 30, 2019.